OptiBrand Rx

Brand positioning firm focusing
on healthcare industry. Our mission is to help healthcare marketers make better-informed, data-driven strategic decisions.

OptiBrand Rx develops, differentiates and validates global brand positioning for new and existing products in the pharmaceutical, biotechnology, medical device and OTC healthcare industries. Pharmaceutical marketing is a high risk business. Surprisingly, too many brand positioning decisions are based on incomplete research. The gaps drag you down. Critical decisions become terminal. You fall short

of your goal. We can help you avoid those pitfalls. OptiBrand Rx is the trusted partner you need. Our research validates your best direction so your messaging and promotion resonate with your target audiences. Differentiate. Give prescribers – and patients – a reason to love your brand™. When they love it, they choose it over your competitors’. And when that happens, you win!

04/29/2026

Today we highlight Odomzo® (sonidegib), a targeted therapy designed to treat locally advanced basal cell carcinoma (BCC) in adults when surgery or radiation are no longer viable options.

Odomzo works by inhibiting the Hedgehog signaling pathway, specifically targeting the Smoothened (SMO) protein, a key driver in the uncontrolled cell growth seen in certain skin cancers. By blocking this pathway, it helps slow or stop tumor progression at a molecular level.

Basal cell carcinoma is often treatable with localized approaches, but for patients with advanced disease, therapeutic options become significantly more limited. Targeted treatments like Odomzo represent the critical shift of moving beyond conventional interventions to address the biology of the disease itself.

OptiBrand values innovations that bring precision to oncology, especially in cases where standard care pathways fall short, and new mechanisms can redefine what’s possible for patients.

Learn more: https://www.odomzo.com/

04/22/2026

Today we highlight Xofigo®, a targeted alpha therapy indicated for patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases.

Xofigo uses an alpha-emitting radioisotope (radium-223) that selectively targets areas of increased bone turnover, delivering localized radiation that induces double-strand DNA breaks in tumor cells while helping limit damage to surrounding tissue.

Bone metastases represent a major clinical challenge in advanced prostate cancer, often contributing to pain, skeletal complications, and reduced survival. Targeted radiopharmaceutical approaches such as Xofigo demonstrate how precision oncology continues to expand beyond traditional systemic therapies.

OptiBrand values innovations that bring targeted mechanisms to complex oncology settings where treatment precision can meaningfully impact patient outcomes.

Learn more: https://www.xofigo.com/

04/15/2026

Today we highlight Nemluvio®, a targeted monoclonal antibody designed to address chronic pruritic inflammatory skin diseases, including atopic dermatitis and prurigo nodularis.

Nemluvio works by inhibiting IL-31 signaling, a key neuroimmune pathway strongly associated with itch, inflammation, and skin barrier dysfunction. By targeting the underlying biology of the itch-scratch cycle, Nemluvio helps reduce symptoms that significantly impact quality of life.

As dermatology continues to evolve toward more precise immune modulation, therapies like Nemluvio highlight the importance of targeting specific cytokine pathways to address complex chronic inflammatory conditions.

OptiBrand is proud to spotlight innovations that translate deeper immunologic understanding into meaningful symptom relief for patients living with persistent skin disease.

Learn more: https://www.nemluvio.com/

04/13/2026

We’re thrilled to welcome Chris Arakelian to the team as EVP, Brand Strategy & Growth at OptiBrand Rx.

Chris joins from Wolff Olins, Omnicom’s globally renowned brand consultancy, where she drove new client relationships across both established and emerging brands.

Her experience spans Healthcare and Pharma, Technology, Professional Services, Financial Services, CPG, Retail, Hospitality, Web3, and more, with 100+ wins including J&J, Kenvue, Sage Therapeutics, Uber, Instacart, SAP, Bloomberg, Morgan Stanley, Microsoft, Amazon, and ConsenSys.

Chris has also held senior roles at leading branding agencies CBX and Sterling Brands, where she helped bring category-defining mega brands to life for Unilever, J&J, Gillette, and Kimberly-Clark, including Axe, Acuvue, Venus, and U by Kotex.

Chris builds future-facing brands that resonate in a rapidly evolving global landscape. She partners closely with marketers to turn insight into action, translating research into clear positioning and creating visual and verbal systems that are compliant, distinctive, and culturally relevant.

At OptiBrand Rx, Chris brings a consultative, healthcare-focused approach grounded in human-centered research, real-world insight, and strategic rigor. She will play a key role in helping clients sharpen positioning, break category conventions, and engage stakeholders with clarity and impact.

We’re incredibly happy to have her on the team and excited for what’s ahead.

04/11/2026

Today, we recognize World Parkinson's Day, a moment to drive awareness and accelerate action.

Parkinson’s is the fastest growing neurological disease in the world, affecting more than 8.5 million people globally, and that number continues to rise. In just the last 25 years, cases have doubled, and they are expected to more than double again in the decades ahead.

This is not slowing down. It is a call to move faster.

Across the world, leaders in research, healthcare, and innovation are pushing boundaries to better understand the disease, unlock new treatments, and improve patient outcomes.

At OptiBrand, we stand with the brands driving this progress. We are proud to support the work that is advancing science and shaping the future of care.

Learn more: https://worldparkinsonsday.com/

04/08/2026

Today we highlight Hyrnuo® (sevabertinib), a targeted therapy recently granted FDA accelerated approval for patients with HER2-mutated non-small cell lung cancer (NSCLC) who have progressed following prior systemic treatment.

Hyrnuo is an oral tyrosine kinase inhibitor designed to block HER2 (ERBB2) signaling pathways that drive tumor growth in a subset of lung cancers with high unmet need.

HER2 mutations occur in a relatively small percentage of NSCLC cases, making precise molecular targeting essential to improving outcomes and expanding treatment options in later lines of therapy.

As oncology continues to advance toward biomarker-driven care, therapies like Hyrnuo highlight the importance of identifying actionable mutations and delivering more personalized treatment strategies.

At OptiBrand, we’re proud to spotlight innovations that help translate molecular insight into meaningful therapeutic progress.

Learn more: https://www.hyrnuohcp.com/

03/25/2026

Today we highlight Skytrofa® (lonapegsomatropin-tcgd), a long-acting growth hormone therapy designed to reduce treatment burden for patients living with growth hormone deficiency (GHD).

Skytrofa reinforces the clinical value of once-weekly administration, offering an alternative to daily injections while supporting consistent growth hormone exposure over time.

By leveraging sustained-release prodrug technology, Skytrofa helps simplify treatment routines for children and families managing a chronic endocrine condition where adherence plays a critical role in long-term outcomes.

We are proud to spotlight innovations that improve not only therapeutic performance, but also the everyday treatment experience for patients.

Learn more: https://investors.ascendispharma.com/

03/21/2026

Today, on World Down Syndrome Day, we honor the individuals in the Down syndrome community whose joy, resilience, and unique light make a lasting impact on the world.

We are proud to support GiGi's Playhouse Long Island and GiGi's Playhouse Miami , both of which are committed to empowering individuals with Down syndrome and fostering more inclusive communities.

At OptiBrandRx, we are grateful for the opportunity to support their mission and proud to call them close friends.

03/18/2026

Today we highlight Astepro® Allergy (azelastine nasal spray), a steroid-free intranasal antihistamine designed to provide fast, effective relief from common allergy symptoms such as nasal congestion, sneezing, and a runny or itchy nose.

Unlike traditional oral antihistamines, Astepro works directly in the nose, blocking histamine, which is the key driver behind allergic reactions, at the source. This targeted mechanism helps relieve symptoms quickly, with onset as fast as 30 minutes and lasting up to 24 hours.

Indicated for:

• Relief of seasonal and perennial allergic rhinitis.
• Adults and children (age-dependent use).
• Symptoms including congestion, sneezing, and nasal itching.

As allergy management continues to evolve, therapies like Astepro reflect a shift toward fast-acting, localized treatment options that improve everyday comfort without systemic burden.

OptiBrand, is proud to spotlight innovations that help patients breathe easier and regain control of their daily lives.

Learn more: https://www.asteproallergy.com/

03/13/2026

Meet Ariana Bancu, Ph.D.

Our Director of Research, Europe at OptiBrand Rx.

Ariana believes research is most powerful when it tells a story. With deep expertise across qualitative and quantitative methods, she transforms complex data into clear, compelling narratives that uncover the “why” behind HCP and patient behavior.

From 2019 to 2022, she served as an Assistant Professor at Northeastern Illinois University in Chicago, where she managed her own research lab, led teams of researchers, secured funding, and taught courses in linguistics to more than 400 students. Through this work, she developed and strengthened the research and communication skills that now define her approach: designing thoughtful surveys, conducting interviews, synthesizing findings, and sharing insights at international conferences.

In 2023, Ariana transitioned to OptiBrand Rx. Today, as Director of Research in Europe at the company, she designs studies that not only inform brand strategy but also reveal the human stories driving clinical and patient decisions.

For Ariana, research isn’t just about answering questions; it’s about challenging assumptions, uncovering hidden needs, and making insights transformative. That commitment reflects OptiBrand’s values: bringing clarity, foresight, and humanity to every healthcare strategy.

03/11/2026

Today we highlight Orilissa® (elagolix), an oral GnRH antagonist developed to help manage moderate to severe endometriosis pain, a condition that affects millions of women yet is still widely underdiagnosed and often misunderstood.

By reducing ovarian hormone production, Orilissa helps alleviate pain associated with endometriosis, including painful periods, pelvic discomfort, and pain during in*******se. Its oral, non-injectable formulation provides a treatment option that many women can incorporate more easily into daily life.

Approved for:

• Management of moderate to severe endometriosis-associated pain.
• Use under the guidance of a healthcare professional.

OptiBrand is proud to spotlight therapies designed to address unmet needs in women’s health, bringing effective, evidence-driven solutions to conditions that have long required greater attention and understanding.

Learn more: https://www.orilissa.com/

03/08/2026

Today we recognize the voices that bring new perspectives, challenge ideas, and move organizations forward.

Across industries, women are shaping conversations, driving innovation, and leading meaningful change. At OptiBrand, many of those voices belong to the talented women on our team — in fact, 55% of our team is made up of talented women who contribute every day as strategists, creators, problem solvers, and leaders.

Their ideas strengthen the work we do and push our thinking further.

Today we honor their creativity, dedication, and the impact they continue to make within our organization and beyond.

On International Women’s Day, we recognize the women whose perspectives, leadership, and determination continue to shape our work — and the future we are building together.

Address

26 Park Street, Ste 2061
Montclair, NJ
07042

Website

http://www.optibrandrx.com/, http://www.healthcarebrandpositioning.com/, http://www.pharmabrandpositioning.com/

Alerts

Be the first to know and let us send you an email when OptiBrand Rx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to OptiBrand Rx:

Shortcuts

Want your practice to be the top-listed Clinic in Montclair?